Anaphylaxis Checklist for Pharmacists

pdfAnaphylaxis Checklist for Pharmacists87.46 KB 

Checklist for pharmacists anaphylaxis 2021There are two brands of adrenaline injectors, EpiPen® and Anapen®:

  • EpiPen® (300 mcg) and EpiPen® Jr (150 mcg) are available in Australia on the PBS, and in New Zealand.
  • Anapen® 500, Anapen® 300 and Anapen® 150 are available in Australia on the PBS.

Adrenaline injectors are prescribed as follows:

  • 150 mcg devices for children weighing 7.5 to 20kg.
  • 300 mcg devices for children weighing over 20kg and adults, including pregnant women.
  • 500 mcg or 300 mcg devices for children weighing over 50kg and adults, including pregnant women.
  1. Dispense prescribed adrenaline (epinephrine) injectors
    • Dispense prescribed injectors and check that the dose is appropriate (see above). 
    • Check that the patient has been prescirbed two devices, which are rebated by the PBS in Australia. No devices are currently rebated by Pharmac in New Zealand.
    • Remind the customer (patient and/or carer) to check and note the expiry date of their injector/s. 
    • Check that the patient has an ASCIA Action Plan for Anaphylaxis (RED) that should have been completed by their doctor or nurse practitioner.
    • Reinforce the need for the patient to always carry their adrenaline injector and ASCIA Action Plan.
    • Check that the patient’s asthma is well managed and refer them back to their doctor or nurse practitioner if further action is required. Patients at risk of severe allergic reactions (anaphylaxis) who have asthma that is not well controlled are at increased risk of fatal anaphylaxis.
  2. Dispense non-prescribed adrenaline injectors
    • Dispense adrenaline injector/s to customers (patients/carers or organisations) for use in addition to prescribed devices or in first aid kits. Non-prescribed devices are not rebated by PBS or Pharmac.
    • Remind the customer to check and note the expiry date of their adrenaline injector/s.
    • Check that the customer has an ASCIA First Aid Plan for Anaphylaxis (ORANGE) that should be stored with the non-prescribed device/s. These plans are available at www.allergy.org.au/anaphylaxis
  3. Provide adrenaline injector advice, education and training
    • Teach the customer how to use their prescribed or non-prescribed adrenaline injector/s using a trainer device. Trainer devices are available from the supplier or patient organisations (Allergy & Anaphylaxis Australia www.allergyfacts.org.au or Allergy New Zealand www.allergy.org.nz).
    • Educate the customer about correct storage of adrenaline injectors, away from excessive heat or cooling. www.allergy.org.au/hp/anaphylaxis/adrenaline-autoinjector-storage-expiry-and-disposal
    • Ensure the customer understands that adrenaline is the first line treatment for anaphylaxis and that antihistamines should not be used for the treatment for anaphylaxis. If antihistamines are used to treat mild to moderate allergic reactions, only non-sedating antihistamines should be used.
  4. Be prepared for an anaphylaxis emergency
    • Train staff to recognise the signs and symptoms of anaphylaxis, how to position the patient, how to administer adrenaline injectors and to phone an ambulance immediately afterwards.
    • Display ASCIA Action First Aid Plans for Anaphylaxis to assist staff in recognising and responding to an anaphylaxis emergency.

For adrenaline injector supply updates check www.allergy.org.au/members/adrenaline-autoinjector-availability

© ASCIA 2021

ASCIA is the peak professional body of clinical immunology/allergy specialists in Australia and New Zealand.

Updated September 2021

Mod ASCIA Member
Donate to AIFA
go to NAS website
ASCIA Member Login
ASCIA Update

Information for the community about allergic diseases, immunodeficiencies and other immune diseases.
See latest edition here...
Join our mailing list:

About ASCIA

ASCIA is the peak professional body of clinical immunology and allergy in Australia and New Zealand
ASCIA promotes and advances the study and knowledge of allergy and other immune diseases

Quick Links

About ASCIA

ASCIA is a registered trademark of the Australasian Society of Clinical Immunology and Allergy. All content is subject to copyright for the Australasian Society of Clinical Immunology and Allergy. Read more...

The content for the website is developed and approved by ASCIA Committee and ASCIA Working Party Members. Read more...

Disclaimer I Privacy

The ASCIA website is intended for use by ASCIA members, health professionals and the general public. The content provided is for education, communication and information purposes only and is not intended to replace or constitute medical advice or treatments. Read more...

ASCIA respects your privacy. Read our privacy policy here...

Sponsors | Advertising

ASCIA does not endorse products from sponsoring organisations, nor is it influenced by sponsoring organisations with regard to the content of education programs and websites. 

The ASCIA website does not accept advertising. Any link to a third-party website does not imply any endorsement by ASCIA.

Accreditiation

healthdirect

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information: verify here.